Michael J Duffy
Michael J Duffy
St Vincent's University Hospital and University College Dublin
Verified email at ucd.ie
Title
Cited by
Cited by
Year
The urokinase‐type plasminogen activator system in cancer metastasis: a review
PA Andreasen, L Kjøller, L Christensen, MJ Duffy
International journal of cancer 72 (1), 1-22, 1997
20251997
Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?
MJ Duffy
Clinical chemistry 47 (4), 624-630, 2001
8202001
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients
MP Look, WLJ Van Putten, MJ Duffy, N Harbeck, IJ Christensen, ...
Journal of the National Cancer Institute 94 (2), 116-128, 2002
7222002
Metalloproteinases: role in breast carcinogenesis, invasion and metastasis
MJ Duffy, TM Maguire, A Hill, E McDermott, N O'Higgins
Breast cancer research 2 (4), 1-6, 2000
7152000
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers
CM Sturgeon, MJ Duffy, UH Stenman, H Lilja, N Brunner, DW Chan, ...
Clinical chemistry 54 (12), e11-e79, 2008
685*2008
Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use
MJ Duffy, A van Dalen, C Haglund, L Hansson, E Holinski-Feder, ...
European journal of cancer 43 (9), 1348-1360, 2007
5672007
Survivin: a new target for anti-cancer therapy
BM Ryan, N O’Donovan, MJ Duffy
Cancer treatment reviews 35 (7), 553-562, 2009
5082009
Serum tumor markers in breast cancer: are they of clinical value?
MJ Duffy
Clinical chemistry 52 (3), 345-351, 2006
5012006
The urokinase plasminogen activator system: role in malignancy
MJ Duffy
Current pharmaceutical design 10 (1), 39-49, 2004
4892004
Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines
MJ Duffy, A van Dalen, C Haglund, L Hansson, R Klapdor, R Lamerz, ...
European journal of cancer 39 (6), 718-727, 2003
4872003
The role of proteolytic enzymes in cancer invasion and metastasis
MJ Duffy
Clinical & experimental metastasis 10 (3), 145-155, 1992
4521992
Proteases as prognostic markers in cancer.
MJ Duffy
Clinical Cancer Research 2 (4), 613-618, 1996
4321996
Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer
MJ Duffy, D Reilly, C O'Sullivan, N O'Higgins, JJ Fennelly, P Andreasen
Cancer research 50 (21), 6827-6829, 1990
4061990
Tumor markers in breast cancer–European Group on Tumor Markers recommendations
R Molina, V Barak, A van Dalen, MJ Duffy, R Einarsson, M Gion, H Goike, ...
Tumor Biology 26 (6), 281-293, 2005
3922005
Urokinase‐plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report
MJ Duffy, L O'siorain, P O'grady, D Devaney, JJ Fennelly, HJ Lijnen
Cancer 62 (3), 531-533, 1988
3891988
Cancer invasion and metastasis: changing views
MJ Duffy, PM McGowan, WM Gallagher
The Journal of pathology 214 (3), 283-293, 2008
3792008
Survivin: a promising tumor biomarker
MJ Duffy, N O’Donovan, DJ Brennan, WM Gallagher, BM Ryan
Cancer letters 249 (1), 49-60, 2007
3662007
Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report
MJ Duffy, C Sturgeon, R Lamerz, C Haglund, VL Holubec, R Klapdor, ...
Annals of Oncology 21 (3), 441-447, 2010
3582010
CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use
MJ Duffy, JM Bonfrer, J Kulpa, GJS Rustin, G Soletormos, GC Torre, ...
International Journal of Gynecologic Cancer 15 (5), 2005
3492005
Community based cognitive therapy in the treatment of post-traumatic stress disorder following the Omagh bomb
K Gillespie, M Duffy, A Hackmann, DM Clark
Behaviour Research and Therapy 40 (4), 345-357, 2002
3402002
The system can't perform the operation now. Try again later.
Articles 1–20